Estimating the rate of progressive visual field damage in those with open-angle glaucoma, from cross-sectional data

Investigative Ophthalmology and Visual Science

Volumn 49, Issue 1, 2008, Pages 66-76

  Broman, Aimee Teo ^a   Quigley, Harry A ^a   West, Sheila K ^a,b   Katz, Joanne ^a,b   Munoz, Beatriz ^a   Bandeen Roche, Karen ^b   Tielsch, James M ^a,b   Friedman, David S ^a,b   Crowston, Jonathan ^c   Taylor, Hugh R ^c   Varma, Rohit ^d   Leske, M Cristina ^e   Bengtsson, Boel ^f   Heijl, Anders ^f   He, Mingguang ^g,h   Foster, Paul J ^g,i  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e STONY BROOK UNIVERSITY   (United States)

^f LUND UNIVERSITY   (Sweden)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h SUN YAT SEN UNIVERSITY   (China)

ⁱ MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DISEASE EXACERBATION; ETHNICITY; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; OPEN ANGLE GLAUCOMA; OPTIC NERVE DISEASE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; VISUAL FIELD DEFECT; AGING; CROSS-SECTIONAL STUDY; ETHNIC GROUP; ETHNOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROBABILITY; SEX DIFFERENCE; STATISTICAL MODEL; VISUAL DISORDER; VISUAL FIELD;

ADULT; AGED; AGED, 80 AND OVER; AGING; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; ETHNIC GROUPS; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PREVALENCE; PROBABILITY; RISK FACTORS; SEX FACTORS; VISION DISORDERS; VISUAL FIELDS;

EID: 39549106321     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.07-0866     Document Type: Article

References (58)

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262-267.
2. Friedman DS, Wolfs RC, O'Colmain BJ, et al. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol. 2004;122:532-538.
3. Ellwein LB, Urato CJ. Use of eye care and associated charges among the Medicare population: 1991-1998. Arch Ophthalmol. 2002;120:804-811.
4. Schappert SM. Office visits for glaucoma: United States, 1991-92; advance data from vital and health statistics. Hyattsville, MD, National Center for Health Statistics; 1995:262.
5. Fiscella RG, Green A, Patuszynski DH, Wilensky J. Medical therapy cost considerations for glaucoma. Am J Ophthalmol. 2003;136:18-25.
6. Hourihan F, Mitchell P. Factors associated with use of glaucoma medications in a population of older people: The Blue Mountains Eye Study. Aust NZ J Ophthalmol. 1999;27:176-179.
7. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998;126:487-497.
8. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268-1279.
9. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701-713.
10. Eid TM, Spaeth GL, Bitterman A, Steinmann WC. Rate and amount of visual loss in 102 patients with open-angle glaucoma followed up for at least 15 years. Ophthalmology. 2003;110:900-907.
11. Kwon YH, Kim CS, Zimmerman MB, Alward WL, Hayreh SS. Rate of visual field loss and long-term visual outcome in primary open-angle glaucoma. Am J Ophthalmol. 2001;132:47-56.
12. Lee AC, Sample PA, Blumenthal EZ, Berry C, Zangwill L, Weinreb RN. Infrequent confirmation of visual field progression. Ophthalmology. 2002;109:1059-1065.
13. Rasker MT, van den Enden EA, Bakker D, Hoyng PF. Rate of visual field loss in progressive glaucoma. Arch Ophthalmol. 2000;118:481-488.
14. Smith SD, Katz J, Quigley HA. Analysis of progressive change in automated visual fields in glaucoma. Invest Ophthalmol Vis Sci. 1996;37:1419-1428.
15. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 6. Treatment group differences in visual field changes. Am J Ophthalmol. 1995;120:10-22.
16. The Advanced Glaucoma Intervention Study (AGIS): 4. Comparison of treatment outcomes within race: seven-year results. Ophthalmology. 1998;105:1146-1164.
17. Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108:1943-1953.
18. Quigley HA, Vitale S. Models of open-angle glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci. 1997;38:83-91.
19. Grodum K, Heijl A, Bengtsson B. A comparison of glaucoma patients identified through mass screening and in routine clinical practice. Acta Ophthalmol Scand. 2002;80:627-631.
20. Leske MC, Connell AM, Wu SY, et al. Incidence of open-angle glaucoma: the Barbados Eye Studies. The Barbados Eye Studies Group. Arch Ophthalmol. 2001;119:89-95.
21. Mukesh BN, McCarty CA, Rait JL, Taylor HR. Five-year incidence of open-angle glaucoma: the visual impairment project. Ophthalmology. 2002;109:1047-1051.
22. Wilson MR, Kosoko O, Cowan CL Jr, et al. Progression of visual field loss in untreated glaucoma patients and glaucoma suspects in St. Lucia, West Indies. Am J Ophthalmol. 2002;134:399-405.
23. Bengtsson BO. Incidence of manifest glaucoma. Br J Ophthalmol. 1989;73:483-487.
24. Leske MC, Wu SY, Honkanen R, et al. Nine-year incidence of open-angle glaucoma in the Barbados Eye Studies. Ophthalmology. 2007;114:1058-1064.
25. Quigley HA, Tielsch JM, Katz J, Sommer A. Rate of progression in open-angle glaucoma estimated from cross-sectional prevalence of visual field damage. Am J Ophthalmol. 1996;122:355-363.
26. Leske MC, Ederer F, Podgor M. Estimating incidence from age-specific prevalence in glaucoma. Am J Epidemiol. 1981;113:606-613.
27. Bengtsson B. Survival of elderly ophthalmic out-patients. Acta Ophthalmol (Copenh). 1984;62:725-730.
28. Borger PH, van Leeuwen R, Hulsman CA, et al. Is there a direct association between age-related eye diseases and mortality? The Rotterdam Study. Ophthalmology. 2003;110:1292-1296.
29. Klein R, Klein BE, Moss SE. Age-related eye disease and survival: The Beaver Dam Eye Study. Arch Ophthalmol. 1995;113:333-339.
30. Shrum KR, Hattenhauer MG, Hodge D. Cardiovascular and cerebrovascular mortality associated with ocular pseudoexfoliation. Am J Ophthalmol. 2000;129:83-86.
31. Grodum K, Heijl A, Bengtsson B. Glaucoma and mortality. Graefes Arch Clin Exp Ophthalmol. 2004;242:397-401.
32. Lee DJ, Gomez-Marin O, Lam BL, Zheng DD. Glaucoma and survival: the National Health Interview Survey 1986-1994. Ophthalmology. 2003;110:1476-1483.
33. Lee AJ, Wang JJ, Kifley A, Mitchell P. Open-angle glaucoma and cardiovascular mortality: the Blue Mountains Eye Study. Ophthalmology. 2006;113:1069-1076.
34. Minassian DC, Reidy A, Coffey M, Minassian A. Utility of predictive equations for estimating the prevalence and incidence of primary open angle glaucoma in the UK. Br J Ophthalmol. 2000;84:1159-1161.
35. Wu SY, Nemesure B, Leske MC. Observed versus indirect estimates of incidence of open-angle glaucoma. Am J Epidemiol. 2001;153:184-187.
36. Sloan FA, Brown DS, Carlisle ES, Ostermann J, Lee PP. Estimates of incidence rates with longitudinal claims data. Arch Ophthalmol. 2003;121:1462-1468.
37. Schoff EO, Hattenhauer MG, Ing HH, et al. Estimated incidence of open-angle glaucoma in Olmsted County, Minnesota. Ophthalmology. 2001;108:882-886.
38. Foster PJ, Buhrmann R, Quigley HA, Johnson GJ. The definition and classification of glaucoma in prevalence surveys. Br J Ophthalmol. 2002;86:238-242.
39. Wolfs RC, Borger PH, Ramrattan RS, et al. Changing views on open-angle glaucoma: definitions and prevalences - The Rotterdam Study. Invest Ophthalmol Vis Sci. 2000;41:3309-3321.
40. Tielsch JM, Sommer A, Katz J, Royall RM, Quigley HA, Javitt J. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. JAMA. 1991;266:369-374.
41. Quigley HA, West SK, Rodriguez J, Munoz B, Klein R, Snyder R. The prevalence of glaucoma in a population-based study of Hispanic subjects: Proyecto VER. Arch Ophthalmol. 2001;119:1819-1826.
42. Friedman DS, Jampel HD, Munoz B, West SK. The prevalence of open-angle glaucoma among blacks and whites 73 years and older: the Salisbury Eye Evaluation Glaucoma Study. Arch Ophthalmol. 2006;124:1625-1630.
43. Varma R, Ying-Lai M, Francis BA, et al. Prevalence of open-angle glaucoma and ocular hypertension in Latinos: the Los Angeles Latino Eye Study. Ophthalmology. 2004;111:1439-1448.
44. Leske MC, Connell AM, Schachat AP, Hyman L. The Barbados Eye Study: prevalence of open angle glaucoma. Arch Ophthalmol. 1994;112:821-829.
45. Weih LM, Nanjan M, McCarty CA, Taylor HR. Prevalence and predictors of open-angle glaucoma: results from the visual impairment project. Ophthalmology. 2001;108:1966-1972.
46. Foster PJ, Oen FT, Machin D, et al. The prevalence of glaucoma in Chinese residents of Singapore: a cross-sectional population survey of the Tanjong Pagar district. Arch Ophthalmol. 2000;118:1105-1111.
47. He M, Foster PJ, Ge J, et al. Prevalence and clinical characteristics of glaucoma in adult Chinese: a population-based study in Liwan District, Guangzhou. Invest Ophthalmol Vis Sci. 2006;47:2782-2788.
48. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003;121:48-56.
49. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:714-720.
50. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429-440.
51. Rudnicka AR, Mt-Isa S, Owen CG, Cook DG, Ashby D. Variations in primary open-angle glaucoma prevalence by age, gender, and race: a Bayesian meta-analysis. Invest Ophthalmol Vis Sci. 2006;47:4254-4261.
52. The AGIS Investigators. Effect of cataract on visual field and visual acuity. The Advanced Glaucoma Intervention Study, report 6. Arch Ophthalmol. 2000;118:1639-1652.
53. Smith SD, Katz J, Quigley HA. Effect of cataract extraction on the results of automated perimetry in glaucoma. Arch Ophthalmol. 1997;115:1515-1519.
54. Katz J. Scoring systems for measuring progression of visual field loss in clinical trials of glaucoma treatment. Ophthalmology. 1999;106:391-395.
55. Artes PH, Iwase A, Ohno Y, Kitazawa Y, Chauhan BC. Properties of perimetric threshold estimates from Full Threshold, SITA Standard, and SITA Fast strategies. Invest Ophthalmol Vis Sci. 2002;43:2654-2659.
56. Bengtsson B, Heijl A. Comparing significance and magnitude of glaucomatous visual field defects using the SITA and Full Threshold strategies. Acta Ophthalmol Scand. 1999;77:143-146.
57. Budenz DL, Rhee P, Feuer WJ, McSoley J, Johnson CA, Anderson DR. Comparison of glaucomatous visual field defects using standard full threshold and Swedish interactive threshold algorithms. Arch Ophthalmol. 2002;120:1136-1141.
58. Quigley HA, Friedman DS, Hahn SR. Evaluation of practice patterns for the care of open-angle glaucoma compared with claims data. The Glaucoma Adherence and Persistency Study. Ophthalmology. 2007;114:1599 -1606; discussion 1597-1598.